The following poll was posted on Twitter Jan 25, 2024:
Interestingly, the leading response was neither!
Let’s look at what the guidelines say:
2020 International Society on Thrombosis and Haemostasis (ISTH):
The ISTH recommends using both rituximab and caplacizumab for acquired TTP, first acute event (conditional recommendation).
2023 British Society of Haematology (BSH):
The BSH recommends initiating therapy with monoclonal anti-CD20 therapy within 3 days of acute acquired TTP (1B), and caplacizumab upon confirmation of acute iTTP (1A).
UpToDate (expert opinion):1
UTD recommends initiating rituximab once acquired TTP is confirmed, and caplacizumab for those with acquired TTP and severe features (though they acknowledge a broad range of preferences for using caplacizumab).
Primary studies:
